FDA Approves Higher Dose of Biogen Genetic Disorder Drug

The FDA has approved a higher-dose version of Biogen's drug for a rare genetic disorder. The new regimen will be available to U.S. patients in the coming weeks.

Xurve View
Insights:

The United States Food and Drug Administration has approved a higher-dose version of a treatment for a rare genetic disorder that causes progressive muscle weakness, according to an announcement by Biogen Inc. on Monday. The approval provides a new therapeutic path for patients after the regulator previously declined the application last year due to a need for further technical data.

A sign identifies a Biogen facility in Cambridge, Massachusetts, where the company conducts its operations. REUTERS/Brian Snyder